---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-365556"
form_type: "8-K"
ticker: "GENB"
cik: "0002100782"
company_name: "Generate Biomedicines, Inc."
filed_at: "2026-08-25T23:28:57+00:00"
generated_at: "2026-08-26T10:05:50.338513+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Generate:Biomedicines reveals GB-0895 data: ~98-day half-life, 6-month biomarker control

## Summary
- Phase 1 (GB-0895-101): single 300 mg SC cuts BEC, FeNO, IL-5, IL-13 in mild-moderate asthma for ≥6 months; ~98-day half-life.
- COPD Part C (N=40): biomarker reductions from Month 1 sustained ≥6 months; 300 mg comparable to 600 mg; no related SAEs.
- Phase 3 trials SOLAIRIA-1 (NCT07276724) & SOLAIRIA-2 (NCT07359846) each N=786, severe uncontrolled asthma; primary endpoint AAER at 52 weeks.
- GB-0895 well-tolerated: majority of TEAEs mild-moderate; all ISRs Grade 1; no anti-drug antibody impact on half-life.

## SEC filing metadata
- accession: 0001193125-26-365556
- form_type: 8-K
- ticker: GENB
- cik: 0002100782
- company_name: Generate Biomedicines, Inc.
- filed_at: 2026-08-25T23:28:57+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2100782/000119312526365556/0001193125-26-365556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2100782/000119312526365556/ck0002100782-20260825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-365556
- JSON: https://secwatch.observer/filing/0001193125-26-365556.json
- Plain text: https://secwatch.observer/filing/0001193125-26-365556.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.